Stockreport

SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

AstraZeneca PLC Ordinary Shares  (AZN) 
Last astrazeneca plc ordinary shares earnings: 2/5 04:00 pm Check Earnings Report
US:NYSE Investor Relations: astrazeneca.com/investor-relations.html
PDF First-in-class SAPHNELO Pen now offers greater flexibility and convenience, reaching a wider group of patients WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s SAPHNE [Read more]